Breaking News, Promotions & Moves

Thermo Fisher Names Corp. Development Head

Paul G. Parker to serve as senior vice president, strategy and corporate development, including corporate social responsibility

By: Kristin Brooks

Managing Editor, Contract Pharma

Thermo Fisher Scientific Inc. has appointed Paul G. Parker as senior vice president, strategy and corporate development, including corporate social responsibility, effective April 15. Parker will report to Marc N. Casper, chairman, president and chief executive officer, and will be based in Waltham, MA.

Parker previously served for six years as co-chairman of Global Mergers & Acquisitions at Goldman Sachs & Co., and as a member of the firm’s Partnership Committee. His investment banking career spans 35 years, having held numerous global operating and senior client relationship roles at Goldman Sachs and other leading financial services firms including Barclays, Lehman Brothers and J.P. Morgan.

“We are pleased to welcome Paul to the Thermo Fisher leadership team as we broaden our deep bench of executive talent,” said Casper. “With more than three decades of investment banking experience, Paul is a highly respected leader in the global banking and finance community and brings skills that will complement our team. Having worked closely with Paul over the years, I am confident he will make significant contributions to our ongoing success as we continue to execute our proven growth strategy and create shareholder value.” 

Shiraz Ladiwala, currently head of strategy and corporate development for Thermo Fisher, announced plans to retire from the company in March 2021. He will serve as senior vice president, integrations, until that time and will primarily lead integration planning for the QIAGEN acquisition, announced on March 3, 2020.

Casper concluded, “On behalf of the entire Thermo Fisher team, I would like to thank Shiraz for his significant contributions during his outstanding 20-plus year career with us. His insights and leadership have guided us through significant value creation and I’m pleased that we will continue to benefit from his expertise in the coming year.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters